Axonics, Inc. to be acquired by Boston Scientific in groundbreaking deal.

Read More:

Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Boston Scientific Corporation, a leading medical device company, has recently announced that it has entered into a definitive agreement to acquire Axonics, Inc., a pioneering developer of rechargeable sacral neuromodulation (SNM) systems. This strategic move aligns with Boston Scientific’s goal of expanding its presence in the growing field of urology and pelvic health.

Enhancing Boston Scientific’s Urology and Pelvic Health Portfolio

By acquiring Axonics, Boston Scientific aims to enhance its portfolio of cutting-edge solutions for patients suffering from urological and pelvic health disorders. Axonics’ proprietary SNM systems, which offer patients a rechargeable option for long-term therapy, will complement Boston Scientific’s existing portfolio, which includes non-rechargeable SNM systems.

The addition of Axonics’ advanced technology will enable Boston Scientific to provide more personalized and comprehensive solutions to patients who require bladder and bowel dysfunction therapies. The rechargeable feature of Axonics’ SNM systems not only offers greater convenience to patients but also helps reduce healthcare costs by minimizing the need for frequent battery replacement.

Strengthening Boston Scientific’s Global Market Position

This acquisition will further strengthen Boston Scientific’s global market position in the urology and pelvic health space. By combining the expertise and resources of both companies, Boston Scientific will be better positioned to address the unmet needs of patients across the world.

Expanding Access to Innovative Therapies

Through this agreement, Boston Scientific will have the opportunity to expand the availability of Axonics’ innovative SNM systems globally. This will enable more patients to access advanced therapies for the treatment of various bladder and bowel dysfunctions, ultimately improving their quality of life.

A Shared Commitment to Advancing Patient Care

Both Boston Scientific and Axonics are driven by a shared commitment to improving patient care through innovation. By coming together, the companies aim to accelerate the development and commercialization of technologies that can transform the lives of individuals suffering from urological and pelvic health disorders.

The acquisition of Axonics is expected to be accretive to Boston Scientific’s adjusted earnings per share by 2023 and will further contribute to the company’s mission of providing healthcare solutions that make a meaningful difference in patients’ lives.

Conclusion

Boston Scientific’s agreement to acquire Axonics, Inc. marks an important step in the company’s growth strategy within the field of urology and pelvic health. This strategic move will enable Boston Scientific to offer a more comprehensive range of therapies to patients worldwide, while also solidifying its position as a global leader in the medical device industry.

Read More: